|
|
Role of second autologous stem cell transplantation in relapsed multiple myeloma |
|
22 January |
09:15
09:30
|
SC Papendal
Foyer 2
|
|
|
|
Quality of life in RR CLL after MRD-guided treatment with ibrutinib + venetoclax |
|
22 January |
09:30
09:45
|
SC Papendal
Foyer 2
|
|
|
|
Allogeneic stem cell transplantation effective after pathway inhibitor treatments in CLL. |
Speaker:
Michel van Gelder |
22 January |
09:45
10:00
|
SC Papendal
Foyer 2
|
|
|
|
Thrombosis incidence in three multiple myeloma HOVON trials |
Speaker:
Catalina Codreanu |
22 January |
10:00
10:15
|
SC Papendal
Foyer 2
|
|
|
|
Mitapivat in Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II |
|
22 January |
10:15
10:30
|
SC Papendal
Foyer 2
|
|
|
|
Adaptive Designs in Randomized Clinical Trials: Reanalysis of the HOVON-87/NMSG18 MM trial |
|
22 January |
10:30
10:45
|
SC Papendal
Foyer 2
|
|
